D. Xin Ge’s Lab

Dr. Ge received his undergraduate and master’s education in Chemical / Biochemical Engineering from Tsinghua University, Beijing China. He went to Canada and obtained his Ph.D. from McMaster University in 2008. He had postdoc training for three years at UT-Austin with Prof. George Georgiou on antibody library construction and immune repertoire analysis, then joined the faculty of University of California Riverside. He served as Assistant / Associate Professor of Chemical Engineering, Biochemistry, Bioengineering, and Microbiology. After 10 years in the Golden State, he moved his lab to Texas in 2021.

Dr. Ge’s work focuses on discovery and engineering of biologics, such as monoclonal antibodies (mAbs) and therapeutic enzymes. His lab is committed to inventing enabling methodologies that facilitate biologics development, which are important but difficult or even impossible with current technologies. Bypassing the limits associated with what nature offers, his team applies engineering strategies to streamline a set of in vitro approaches including synthetic library, rational design, functional selection, repertoire sequencing, etc. Combinations of these approaches provide a powerful means for developing highly potent mAbs of biological activities relevant to disease diagnosis and treatment. Many mAbs discovered in Dr. Ge’s lab have showed significant efficacy in various models of cancer, stroke, obesity, and neuropathic pain. In addition, mAbs originated from his group have been licensed to bio-pharm industry for further development and commercialization.

Research Projects:

Highly selective protease-inhibiting mAbs (NIGMS)

Therapeutic mAbs for diabetic neuropathy (DoD)

Anti-snake venom mAbs (NIAID)

Novel bispecific prodrugs for BBB penetration (NINDS)

Combinatorial libraries in mammalian cells


  • Nam DH, Lee KB, Kruchowy E, Pham H, Ge X. Protease Inhibition Mechanism of Camelid-Like Synthetic Human Antibodies. Biochemistry (2020) 59[40]:3802-3812. PMCID: PMC7572768
  • Lee KB, Dunn Z, Lopez T, Mustafa Z, Ge X. Generation of Highly Selective Monoclonal Antibodies Inhibiting a Recalcitrant Protease Using Decoy Designs. Biotechnol Bioeng (2020) 117[12]:3664-3676. PMCID: PMC7855242 
  • Lopez T, Mustafa Z, Chen C, Lee KB, Ramirez A, Benitez C, Luo X, Ji R-R, Ge X. Functional Selection of Protease Inhibitory Antibodies. Proc Natl Acad Sci USA (2019) 116 [33]:16314-16319.  PMCID: PMC6697876
  • Lee KB, Dunn Z, Ge X. Reducing Proteolytic Liability of an MMP-14 Inhibitory Antibody by Site-Saturation Mutagenesis. Protein Sci (2019) 28[3]:643-653.  PMCID: PMC6371627
  • Lopez T, Ramirez A, Benitez C, Mustafa Z, Pham H, Sanchez R, Ge X. Selectivity Conversion of Protease Inhibitory Antibodies. Antibody Therapeutics (2018) 1[2]:75-83. PMCID: PMC7990135
  • Lopez T, Chen C, Ramirez A, Chen KE, Lorenson MY, Benitez C, Mustafa Z, Pham H, Sanchez R, Walker AM, Ge X. Epitope Specific Affinity Maturation Improved Stability of Potent Protease Inhibitory Antibodies. Biotechnol Bioeng (2018) 115[11]:2673-2682.  PMCID: PMC6202216
  • Lopez T, Nam DH, Kaihara E, Mustafa Z, Ge X. Identification of Highly Selective MMP-14 Inhibitory Fabs by Deep Sequencing. Biotechnol Bioeng (2017) 114[6]:1140-1150. PMCID: PMC5398909
  • Nam DH, Fang K, Rodriguez C, Lopez T, Ge X. Generation of Inhibitory Monoclonal Antibodies Targeting Membrane-Type 1 Matrix Metalloproteinase by Motif Grafting and CDR Optimization. Protein Eng Des Sel (2017) 30[2]:113-118. PMCID: PMC6283398
  • Li XC, Wang C, Mulchandani A, Ge X. Engineering Soluble Human Paraoxonase 2 for Quorum Quenching. ACS Chem Biol (2016) 11[11]: 3122-3131. PMID: 27623343
  • Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X. Active-Site MMP-Selective Antibody Inhibitors Discovered from Convex Paratope Synthetic Libraries. Proc Natl Acad Sci USA (2016) 113[52]:14970-14975. PMCID: PMC5206513